Cargando…

Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study

Transdermal tulobuterol, a long-acting beta agonist in a transdermal form, is available in some countries, including Japan, Korea, and China. It may provide an alternative treatment option for the management of chronic obstructive pulmonary disease (COPD) in patients who are unable to effectively us...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Yuichiro, Jo, Taisuke, Makito, Kanako, Matsui, Hiroki, Fushimi, Kiyohide, Yasunaga, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519481/
https://www.ncbi.nlm.nih.gov/pubmed/37746980
http://dx.doi.org/10.1097/MD.0000000000035032
_version_ 1785109707651809280
author Matsuo, Yuichiro
Jo, Taisuke
Makito, Kanako
Matsui, Hiroki
Fushimi, Kiyohide
Yasunaga, Hideo
author_facet Matsuo, Yuichiro
Jo, Taisuke
Makito, Kanako
Matsui, Hiroki
Fushimi, Kiyohide
Yasunaga, Hideo
author_sort Matsuo, Yuichiro
collection PubMed
description Transdermal tulobuterol, a long-acting beta agonist in a transdermal form, is available in some countries, including Japan, Korea, and China. It may provide an alternative treatment option for the management of chronic obstructive pulmonary disease (COPD) in patients who are unable to effectively use inhalers, such as those with acute stroke. This study examined the short-term outcomes of transdermal tulobuterol in patients hospitalized with acute stroke and underlying COPD. Using the Diagnosis Procedure Combination database, a national inpatient database in Japan, we identified patients with stroke and underlying COPD who were hospitalized between July 2010 and March 2021. We performed propensity-score overlap weighting to compare in-hospital death, COPD exacerbation, pneumonia, and cardiac complications between patients who initiated transdermal tulobuterol within 2 days of admission and those who did not use it during hospitalization. Of the 1878 eligible patients, 189 received transdermal tulobuterol within 2 days of admission. After adjusting for baseline variables, transdermal tulobuterol was not associated with a reduction in in-hospital death (18.3% vs 16.1%; odds ratio, 1.17; 95% confidence interval, 0.72–1.90). Additionally, we observed no significant difference in COPD exacerbation, pneumonia, and cardiac complications between both groups. Transdermal tulobuterol was not associated with improving short-term outcomes in patients with acute stroke and underlying COPD. Our study does not support the routine use of transdermal tulobuterol in this patient group. However, further research investigating the long-term efficacy of transdermal tulobuterol in patients with stroke and underlying COPD could help establish its role for the management of these patients.
format Online
Article
Text
id pubmed-10519481
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105194812023-09-26 Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study Matsuo, Yuichiro Jo, Taisuke Makito, Kanako Matsui, Hiroki Fushimi, Kiyohide Yasunaga, Hideo Medicine (Baltimore) 6700 Transdermal tulobuterol, a long-acting beta agonist in a transdermal form, is available in some countries, including Japan, Korea, and China. It may provide an alternative treatment option for the management of chronic obstructive pulmonary disease (COPD) in patients who are unable to effectively use inhalers, such as those with acute stroke. This study examined the short-term outcomes of transdermal tulobuterol in patients hospitalized with acute stroke and underlying COPD. Using the Diagnosis Procedure Combination database, a national inpatient database in Japan, we identified patients with stroke and underlying COPD who were hospitalized between July 2010 and March 2021. We performed propensity-score overlap weighting to compare in-hospital death, COPD exacerbation, pneumonia, and cardiac complications between patients who initiated transdermal tulobuterol within 2 days of admission and those who did not use it during hospitalization. Of the 1878 eligible patients, 189 received transdermal tulobuterol within 2 days of admission. After adjusting for baseline variables, transdermal tulobuterol was not associated with a reduction in in-hospital death (18.3% vs 16.1%; odds ratio, 1.17; 95% confidence interval, 0.72–1.90). Additionally, we observed no significant difference in COPD exacerbation, pneumonia, and cardiac complications between both groups. Transdermal tulobuterol was not associated with improving short-term outcomes in patients with acute stroke and underlying COPD. Our study does not support the routine use of transdermal tulobuterol in this patient group. However, further research investigating the long-term efficacy of transdermal tulobuterol in patients with stroke and underlying COPD could help establish its role for the management of these patients. Lippincott Williams & Wilkins 2023-09-22 /pmc/articles/PMC10519481/ /pubmed/37746980 http://dx.doi.org/10.1097/MD.0000000000035032 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 6700
Matsuo, Yuichiro
Jo, Taisuke
Makito, Kanako
Matsui, Hiroki
Fushimi, Kiyohide
Yasunaga, Hideo
Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title_full Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title_fullStr Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title_full_unstemmed Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title_short Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study
title_sort association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: a retrospective cohort study
topic 6700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519481/
https://www.ncbi.nlm.nih.gov/pubmed/37746980
http://dx.doi.org/10.1097/MD.0000000000035032
work_keys_str_mv AT matsuoyuichiro associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy
AT jotaisuke associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy
AT makitokanako associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy
AT matsuihiroki associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy
AT fushimikiyohide associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy
AT yasunagahideo associationbetweenuseoftransdermaltulobuterolandshorttermoutcomesinpatientswithstrokeandunderlyingchronicobstructivepulmonarydiseasearetrospectivecohortstudy